TrovaGene, Inc. (NASDAQ:TROV)
Maxim Group Upgrades TrovaGene, Inc. (NASDAQ:TROV)’s stock to Buy with no specific Price Target. This rating was issued on 6/15/18. The stock recently closed its previous session at $0.81 by showing a percentage change of -3.11% from its previous day closing price of $0.83.
Price Target is basically a projection of future price of a company’s stock by the expert analysis of investment analysts or investment firms. There may be various price targets for a stock. These analysts and investment firms use various valuation methods to decide a price target for a stock.
Several investment firms issued their expert ratings on TrovaGene, Inc. (NASDAQ:TROV) in which Maxim Group Downgrades TrovaGene, Inc. (NASDAQ:TROV) to Hold with no specific Price Target on 11/10/17. PiperJaffray Downgrades the stock to Underweight on 3/16/17 with no specific Price Target. Cantor Fitzgerald Upgrades the company’s stock to Buy on 8/08/16 with no specific Price Target. Cantor Fitzgerald Downgrades TrovaGene, Inc. (NASDAQ:TROV) to Hold with a price target of $5.
TrovaGene, Inc. (NASDAQ:TROV) currently has a consensus Price Target of $3. While some analysts have a High Price target for the stock of $3 and a Low Price Target of $3.
Several sell side analysts reviewed their recommendations on TrovaGene, Inc. (NASDAQ:TROV) where 0 analyst have rated the stock as Strong Buy, 1 analysts said it’s a Buy, 0 rated the stock as Hold, 0 analysts reported Underperform and 0 analysts gave their recommendations as Sell. (Current Month Yahoo Finance Ratings)
Zacks Investment Research also rated the stock with a value of 1. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, TrovaGene, Inc. (NASDAQ:TROV) reported its Actual EPS of $-0.88/share. The analysts offering Earnings Estimates for the company were believing that TrovaGene, Inc. (NASDAQ:TROV) could bring EPS of $-0.33/share. The difference between Actual EPS and Estimated EPS was -0.55 Percent. Thus the company showed an Earnings Surprise of -166.7 Percent.
TrovaGene, Inc. (NASDAQ:TROV) has a market capitalization of 14.26 Million. The stock traded with the volume of 549089 shares in the last trading session. The stock touched its high share price of $12.00 on 10/18/17 and the stock also touched its Lowest price in the last 52-weeks of trading on 07/26/18 as $0.65. The company has a 1 Year high price target of $3. The stock is currently trading with a distance of 20-Day Simple Moving Average (SMA20) of -1.88%. The Moving Average SMA50 is -0.88% while SMA200 is -67.69%.
TrovaGene, Inc. (NASDAQ:TROV) is currently showing its ROA (Return on Assets) of -128.4%. The Return on Investment (ROI) is at -349.4% while it’s Return on Equity (ROE) value stands at -223.1%. The stock currently shows its YTD (Year to Date) performance of -78.16 percent while its Weekly performance value is -0.49%. The Monthly and Yearly performances are 2.03 percent and -91.5 percent respectively. The Relative Volume value measured for TrovaGene, Inc. (NASDAQ:TROV) is 0.47. The Average Volume (3 months) is 1.17 Million.
The stock currently has its Annual Dividend of $0 and an annual Dividend Yield of 0 Percent. TROV has P/E (Price to Earnings ttm) value of 0, Forward P/E of 0, P/C (Price to cash per share) of 0.64 and Price to Free Cash Flow (P/FCF) value of 0. The stock is showing its Operating Margin of 0 percent.
Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics’ patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism.